Alana Agnes Silva Camargo de Oliveira

Alana Agnes Silva Camargo de Oliveira

Auto-generated profile, based on publicly available information

Alana Agnes Silva Camargo de Oliveira

LABHEx, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, lha do Fundão, CEP 21941-902, Rio de Janeiro, RJ, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
PFPriscila de Souza Furtado
Priscila de Souza Furtado
GVGil Mendes Viana
Gil Mendes Viana
AOAlana Agnes Silva Camargo de Oliveira
Alana Agnes Silva Camargo de Oliveira
Vitor Won-Held RabeloVitor Won-Held Rabelo
Vitor Won-Held Rabelo
ICIngryd Wenderroschy Cerqueira
Ingryd Wenderroschy Cerqueira
PSPlínio Cunha Sathler
Plínio Cunha Sathler
Introduction: Thrombotic disorders are among the leading causes of morbidity and mortality worldwide. Drugs used in the prevention and treatment of atherothrombosis have pharmacokinetic limitations and adverse effects such as hemorrhagic conditions, highlighting the importance of developing more effective antiplatelet agents. Methods: In this work, we synthesized N,N'-disubstituted ureas 3a-3j and evaluated their antiplatelet profiles through in vitro, ex vivo, and in silico studies. Results: The synthesized derivatives exhibited a selective inhibitory profile against platelet aggregation induced by arachidonic acid (AA) in vitro, without significantly affecting other aspects of primary hemostasis and blood coagulation. The compounds that showed inhibition greater than 85% were submitted to the analysis of their potency by calculating the concentration required to inhibit 50% of platelet aggregation induced by AA (IC50). Urea derivative 3a was the most potent with IC50 of 1.45 μM. Interestingly, this derivative inhibited more than 90% of platelet aggregation induced by AA ex vivo, with a similar effect to acetylsalicylic acid. In the hemolysis assay, most of the urea derivatives presented values below 10% suggesting good hemocompatibility. Additionally, the compounds tested at 100 μM also showed no cytotoxic effects in HepG2 and Vero cells. The in silico results suggested that compound 3a may bind to the key residue of COX-1 similar to AA and known COX-1 inhibitors, and the results are also in agreement with our SAR, which suggests that the inhibition of this enzyme is the most likely mechanism of antiplatelet activity. Conclusion: Therefore, these results demonstrated that N,N'-disubstituted ureas are promising candidates for the development of novel antiplatelet agents.